In the latest trading session, 1.07 million Adma Biologics Inc (NASDAQ:ADMA) shares changed hands as the company’s beta touched 0.61. With the company’s most recent per share price at $15.44 changed hands at -$0.34 or -2.15% at last look, the market valuation stands at $3.60B. ADMA’s current price is a discount, trading about -36.85% off its 52-week high of $21.13. The share price had its 52-week low at $3.06, which suggests the last value was 80.18% up since then. When we look at Adma Biologics Inc’s average trading volume, we note the 10-day average is 6.26 million shares, with the 3-month average coming to 5.24 million.
Analysts gave the Adma Biologics Inc (ADMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended ADMA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Adma Biologics Inc’s EPS for the current quarter is expected to be 0.13.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Instantly ADMA was in red as seen in intraday trades today. With action -5.68%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 241.59%, with the 5-day performance at -5.68% in the red. However, in the 30-day time frame, Adma Biologics Inc (NASDAQ:ADMA) is -22.72% down. Looking at the short shares, we see there were 17.08 million shares sold at short interest cover period of 2.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 3.5% from its recent market value. According to analyst projections, ADMA’s forecast low is 14 with 18 as the target high. To hit the forecast high, the stock’s price needs a -16.58% plunge from its current level, while the stock would need to tank 9.33% for it to hit the projected low.
Adma Biologics Inc (ADMA) estimates and forecasts
Year-over-year growth is forecast to reach 57.10% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 105.85M. 4 analysts are of the opinion that Adma Biologics Inc’s revenue for the current quarter will be 110.7M. The estimates for the next quarter sales put growth at 49.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 38.68%. The 2024 estimates are for Adma Biologics Inc earnings to increase by 471.15%.
ADMA Dividends
Adma Biologics Inc is expected to release its next quarterly earnings report on 2024-Nov-06.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.58% of Adma Biologics Inc shares while 82.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 85.00%. There are 82.81% institutions holding the Adma Biologics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 8.1462% of the shares, roughly 18.64 million ADMA shares worth $208.45 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30.
